Türk Nöroşirürji Dergisi 2019 , Vol 29 , Num 3
Glioblastoma
Koray ÖZDUMAN1,Mehmet HACIHANEFİOĞLU1,M. Necmettin PAMİR1
1Acıbadem Mehmet Ali Aydınlar Üniversitesi, Tıp Fakültesi, Nöroşirürji Anabilim Dalı, İstanbul, Türkiye Glioblastoma (GBM) is the most common malignant tumor of the central nervous system and its treatment is complex and complicated in many aspects. Despite an extensive amount of information on this tumor, the treatment is still not curative. However a better understanding of tumor biology has enabled us to improve treatment, improve survival and increase the quality of life. Studies on tumor biology have made the diagnosis more objective and rational treatments possible. The current treatment relies on a combination of surgery, external beam radiotherapy and chemotherapy with alkylating agents. Recurrence is seen in all patients and in this instance treatment options are again surgery, radiotherapy, chemotherapy and antiangiogenic therapy with bevacuzimab. No other treatment has come into routine use. The survival has improved but is still measured in years. Anahtar Kelimeler : Glioblastoma, High grade glioma, Neurosurgery, Molecular markers